Post-earnings recap
Reported
Wed, May 4, 2011
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a loss per share of $0.31, slightly missing expectations. The stock fell by 1.72% following the announcement, reflecting investor concerns over the absence of revenue and guidance. The company is focusing on its clinical trials, which may impact short-term financial performance but could be crucial for future growth.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.31 | N/A | -2.31% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding current financial performance. They emphasized their commitment to advancing clinical programs despite the lack of revenue.
Management did not provide specific details on revenue expectations.
The company is focusing on ongoing clinical trials and future product development.